Aurobindo Pharma has informed that it enclosed copy of the Press Release that is being issued by the Company announcing that CuraTeQ Biologics s.r.o., a step-down subsidiary of the Company has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version.
The above information is a part of company’s filings submitted to BSE.